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ABSTRACT 
 
Purpose: This study investigated the efficacy and safety of cryotherapy, in the form of 
frozen gel gloves, in relation to docetaxel-induced hand and fingernail toxicities. 
 
Patients and methods: After piloting with 21 patients, a consecutive series sample of 
patients (n=53) prescribed docetaxel every three weeks, for a minimum of three cycles, was 
enrolled in this randomised control trial. Participants acted as their own control, with the 
frozen gel glove worn on one randomised hand for 15 minutes prior to infusion, for the 
duration of the infusion, and for 15 minutes of after completion of treatment. Hand and nail 
toxicities were evaluated by two blinded assessors according to CTCAE.v4 criteria. To assess 
the potential for cross-infection of multi-use gloves, microbial culture and sensitivity swabs 
were taken of each glove at every tenth use.  
 
Results: Of the 53 participants enrolled in the main study, 21 provided evaluable data. There 
was a 60% withdrawal rate due to patient discomfort with the intervention. The mean 
incidence and severity of toxicities in all evaluable cycles in control and intervention hands 
respectively were erythroderma Grade 1 (5%/5%); nail discolouration Grade 1 (81%/67%); 
nail loss Grade 1 (19%/19%) and nail ridging Grade 1 (57%/57%). No significant differences 
were determined between hand conditions in terms of time to event, nor in terms of 
toxicity in gloved and non-gloved hands. 
 
Conclusion: While cryotherapy in the form of frozen gloves for the cutaneous toxicities 
associated with docetaxel is safe, its limited efficacy, patient discomfort and some logistical 
issues preclude its use in our clinical setting. 
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BACKGROUND 
Docetaxel is considered one of the most effective agents in the treatment of malignant 
tumours of the lung, breast, ovary, head and neck, stomach and prostate[1, 2]. In common 
with many chemotherapy regimens, a wide profile of short and long-term side effects (or 
‘toxicities’) is associated with docetaxel. These toxicities range from life-threatening to 
those that cause cosmetic changes such as hair loss. Some toxicities of docetaxel, such as 
myelosuppression and hypersensitivity reactions, are well-managed with supportive 
therapies. Others, such as cutaneous reactions of the hands and nails, are relatively 
neglected in the research literature and in clinical practice, despite their recognised 
potential to impair cancer patients’ quality of life and functional status[3, 4]. Between 30% 
and 88%[4-8] of patients receiving docetaxel experience cutaneous side effects of the hand 
ranging from skin and nail disfigurement, blistering, desquamation, pain, infection, and 
impaired treatment-related quality of life and function.  
 
The aetiology of docetaxel-induced cutaneous hand and nail toxicities is uncertain. The 
hypothesis supported by early evidence indicates that soft tissue perfusion of intravenously 
circulating docetaxel instigates the side effects, exerting anti-angiogenic effects on the 
capillaries of the hand and digits, and thence the structures of the skin and nail beds[7-10]. 
Alternatively, it is proposed that docetaxel toxicities are the result of a neurogenically-
mediated inflammatory process within these structures[7, 11]. There is also anecdotal 
evidence suggesting these effects result from the reaction of ultraviolet light with circulating 
drug in the peripheries[7], although the exact mechanism has not been articulated.  
 
One approach that has had some success in preventing selected complications of 
chemotherapy such as oral mucositis[12] and alopecia[13-16] is cryotherapy. It is argued 
that cryotherapy temporarily reduces vascular flow to the target areas, hence reducing their 
exposure to the harmful agent that causes the toxicities. One n=45 case-control study[8] 
based on this hypothesis provided some interesting early data in relation to hand and nail 
toxicities. Using cryotherapy in the form of frozen gel gloves during infusion, Scotte et al 
noted a decrease in the overall incidence of fingernail toxicities from 51% in the control 
hand to 11% in the hand receiving cryotherapy[8]. Additionally, the severity of fingernail 
toxicities was reduced from 22% onycholysis in untreated nails to 0% in nails treated with 
frozen gloves (p=0.0001)[8]. Skin toxicity was noted in 24% of protected hands versus 53% 
in unprotected hands[8]. Patients were described as satisfied with the comfort level of the 
frozen glove intervention in this study. An n=52 study that replicated Scotte et al’s 
approach, and which similarly reported no patient discomfort with the intervention, found 
that nail and skin toxicity was “significantly decreased” in the protected left hand 
(p=0.01)[17]. A larger n=122 case-control investigation also reported that onycholysis and 
skin toxicites were significantly lower in hands protected with frozen gloves (p=0.0001)[18].  
 
However, these studies have several limitations. They appear to have consistently used the 
left hand as the intervention and the right hand as the case control; in a context where it 
can be reasonably argued that right hand dominance could be a confounding variable. In 
addition, the assessors do not appear to have been blinded. A more robust design to test 
the intervention would therefore randomise the hands and blind the assessors. There are 
also safety and logistical considerisations that have not been addressed in the literature. 
Due to financial, space and other resource implications, in most chemotherapy units the 
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glove must be reusable, yet issues related to cross-infection between multiple users of the 
gloves have not been investigated. Chemotherapy patients may be colonised with, or 
exposed to, clinically significant organisms and many patients treated with docetaxel are 
immunocompromised[11]. Hence nosocomial transmission of organisms between the gloves 
and the multiple, vulnerable users of the gloves might occur in the absence of infection 
control protocols.  
 
In summary, cryotherapy for docetaxel-induced nail and skin toxicities of the hand is a 
popular and promising preventative treatment. Yet there is little high level research 
evidence to support its use and there are some concerns regarding its clinical safety. While 
frozen glove therapy has the potential to reduce the cutaneous effects of docetaxel 
treatment, further research incorporating considerations of infection control, blinding of 
assessors, randomisation and sample size is required to justify the implementation of this 
intervention. The randomised control study described in this paper aimed to extend 
previous work to enhance methodological rigour and add new evidence with respect to 
infection control, prior to its possible implementation in a large ambulatory cancer setting. 
 
OBJECTIVE 
This study investigated the efficacy and safety of cryotherapy, in the form of frozen gel 
gloves, with respect to the prevention of docetaxel-induced nail and skin toxicities in cancer 
patients.  
 
METHODS 
Study design 
The study was a single-blinded, randomised control study of taxane-naive patients 
prescribed docetaxel for breast, prostate, lung, head and neck, stomach or ovarian cancer. 
Participant recruitment and data collection occurred between December 2010 and 
December 2012, after ethical approval was obtained from the Princess Alexandra Hospital, 
Queensland University of Technology and Griffith University Human Research Ethics 
Committees. The study was registered as an investigator-initiated clinical device trial with 
the Therapeutic Goods Administration of Australia (CTN 131/2009), and with 
ClinicalTrials.gov (NCT00911352).  
 
Research questions 
1. Does cryotherapy reduce the incidence, severity and time-to-onset of docetaxel-induced 
nail and skin toxicities? 
2. Do patients tolerate cryotherapy to prevent docetaxel-induced nail and skin toxicities? 
3. What is the microbiological profile of frozen gel gloves used to prevent docetaxel-
induced nail and skin toxicities? 
4. What effect does the use of a cotton glove as a barrier between the patient’s skin and 
the surface of the frozen glove have on the microbiological carriage of frozen gel gloves 
used to prevent docetaxel-induced nail and skin toxicities? 
 
Setting, participants and recruitment 
Princess Alexandra Hospital is a large, public metropolitan teaching hospital in southeast 
Queensland, Australia. Between 1800 and 2000 individual patients are treated with 
Page 5 of 12 
 
chemotherapy each year in the service. A prospective, consecutive sample of patients was 
recruited according to the following inclusion criteria: 
1. Prescribed docetaxel as single or multimodal treatment for any cancer diagnosis, for a 
minimum of three cycles 
2. No disorders of the nails or skin of the hand at the start of treatment 
3. Able to provide informed consent. 
 
Exclusion criteria: 
1. Previous treatment with taxane chemotherapy 
2. Medical history of Raynaud’s phenomenon, distal metastases, ungual pathology, 
arteriopathy, cold intolerance, peripheral neuropathy of CTCAE grade 2 or higher 
3. Not fit for participation in the opinion of the treating oncologist. 
 
Patients were identified by their oncologist or cancer care coordinator and referred to the 
project officer, who screened for eligibility, obtained written informed consent, and 
randomised the patients’ left or right hand to the frozen glove intervention or control.  
 
Randomisation 
Envelopes labelled with numbers 1 to 80 were created, along with a corresponding number 
of cards; half marked ‘Right’ and half marked ‘Left’. These cards were shuffled by a QUT 
researcher, external to the study, in groups of ten, and placed within the envelopes (thereby 
the first ten included five left and five right labelled cards, as did the next ten, and the next). 
As each participant was recruited into the study, the next envelope was taken from the pile 
and opened. The hand on this card was the hand that would be gloved in the study.  
 
Cryotherapy intervention 
The control treatment comprised usual care, that is, no cryotherapy intervention. The 
cryotherapy intervention consisted of a frozen glycerine gel-filled glove, covered with a 
permeable fabric. The gloves covered the hand to the wrist, separating the thumb from the 
rest of the hand like a mitten. Consistent with the recommendations of the product 
manufacturer, the gel glove was frozen at minus 250C to minus 300C for at least 12 hours 
prior to use. Freezer temperature was checked and recorded weekly to ensure 
standardisation of glove temperature.    
 
At the time of study commencement, patients usually received docetaxel once every 21 
days for 63 to 189 days (i.e. on three to eleven separate occasions each). Docetaxel was 
administered on day 1 of each cycle. Hence cryotherapy was administered on day 1 of each 
cycle and occurred every 21 days thereafter, concurrent with docetaxel administration. 
During each docetaxel infusion, the patient wore the glove for a total of 90 minutes (15 
minutes before treatment, during the 1-hour docetaxel infusion, and for a further 15 
minutes after infusion). Because of the duration of the infusion, more than one frozen gel 
glove was used to maintain the necessary low temperature of the hand and nails. Gloves 
were therefore changed every 45 minutes, but were checked every 20 minutes and were 
changed more regularly if they did not feel cool to the touch. This procedure aimed to 
ensure the patient’s periphery was vasoconstricted on commencement of the infusion and 
for enough time afterwards to ensure the circulating drug did not reach the target area[11].   
 
Page 6 of 12 
 
Infection control intervention 
In most facilities, the frozen gloves are routinely re-used by patients, and recirculated 
amongst them, although the manufacturer recommends that the gloves are not cleaned by 
wetting the permeable covering. Hence the gloves cannot be cleaned between patients in 
accordance with the Spaulding Classification System[19]. To counter the risk of infection this 
entails, a disposable cotton glove is worn underneath the gel glove. As the disposable cotton 
glove usually reaches only to the wrist, this nonetheless exposes the area of patient skin 
above the wrist to the permeable covering, as the gel glove is longer than most disposable 
cotton gloves.  
 
In this study, to offset the potential infection control risk of this standard practice, a 
modification to the gloving procedure was tested. This comprised the insertion of a 
disposable nitrile glove, between the cotton and gel gloves, which exceeded the length of 
both these gloves. Intervention hands were therefore assigned either a double (disposable 
cotton plus gel) or triple (disposable cotton plus disposable nitrile plus gel) glove set. The 
assignment of the glove set depended on the patient’s baseline microbiological culture and 
sensitivity (MC&S) swabs of epidemiologically-significant microorganisms, including 
multidrug-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Entercoccus (VRE) 
and carbapenem-resistant A. baumannii (CRAB). Triple-gloved patients were assigned into 
Intervention Arm 2 (multi-disease resistant organism [MDRO] negative) or Intervention Arm 
3 (MDRO positive) prior to random assignment of their hands into intervention or control 
groups (see Figure 1). 
 
Insert Figure 1 about here 
 
Outcome variables  
The primary endpoints were a decrease, over the course of treatment, of nail and skin 
toxicities of the gloved hand in terms of: 
1. Incidence  
2. Severity as measured by Common Toxicity Criteria for Adverse Events-Version 4 
(CTCAE.v4) scores. 
 
Secondary endpoints included: 
1. Delayed time to occurrence of any nail or skin toxicity 
2. Patient tolerance of cryotherapy 
3. Decrease in microbial type and load of the frozen gloves, including the absence of 
epidemiologically significant organisms.  
 
Measures  
Chart data, including demographics (age, gender), tumour type and stage, and concomitant 
medications were recorded on the Client Record Form. Disease- and treatment-related data 
were updated at each time point.  
 
Digital photographs of each patient’s intervention and control hands were taken under 
standardised lighting conditions by a medically-trained photographer at baseline and on Day 
1 of each cycle thereafter. Because the final infusion can also affect the nails beyond 
treatment cessation, nail assessments were also undertaken three weeks after the last 
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infusion during routine follow-up. Hand and nail toxicities were assessed for each patient at 
every cycle from the digital photographs by two blinded assessors using the Common 
Toxicity Criteria for Adverse Events Version 4.+0[20], which are the standard criteria in 
cancer clinical trials (refer Table 1). Inter-rater reliability ratings were established between 
assessors at baseline (96.55% agreement between the two assessors) and re-evaluated 6-
monthly thereafter. 
 
Insert Table 1 about here 
 
Patients’ satisfaction with cryotherapy was also assessed during each of the infusions, using 
a 4-point rating system to determine whether patients were dissatisfied (0), not very 
satisfied (1), satisfied (2), or very satisfied (3) with the treatment in terms of glove contact, 
temperature tolerance and immobilisation constraints.  
 
Sites for swabbing of all gloves were standardised to 1) the internal glove surface of the 
back of the hand; 2) the internal glove surface of the palm of the hand; 3) the internal glove 
surface at the tip of the second index finger; and 4) the internal glove surface at tip of the 
thumb. These sites are well-established as problematic for cleaning and decontamination in 
hand hygiene, where carriage of microbial organisms is high[19]. Swabbing of the microbial 
load of the frozen gel glove occurred on every tenth intervention glove at predetermined 
time-points, as outlined in Figure 1.  
 
Insert Figure 1 about here 
Bias  
As commonly encountered in clinical device trials, it was impossible to blind participants or 
project officers to such an obvious intervention, which is a potential source of bias. To 
address this, the toxicities were not graded in the presence of the patient. Photographs of 
the hands were assessed by two blinded assessors who had no contact with the patient at 
any stage.  
 
Study size  
Using Cohen’s method for estimating required sample size, we set the estimated effect size 
at medium (.30) and the power required at .80, with a significance level of .05[21]. 
According to Cohen’s Indices, n=87 were required to power the study. 
 
Statistical methods  
Statistical analyses of the pooled data were conducted by qualified members of the research 
team using SPSS version 21.0. Frequencies and summary descriptive statistics were 
determined for all study variables. Continuous outcome variables are reported as means 
and standard deviations for normally distributed data; otherwise, the median and inter-
quartile range is presented. Proportions are used to summarise categorical variables.  
 
The data for participants who withdrew from the study due to discomfort or logisitcal 
issues, but who had been assessed at four or more data collection points, were included in 
the final analysis. Analyses were not undertaken on an intention-to-treat basis, as a number 
of participants withdrew from the study after only one data collection point, leaving little 
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opportunity for any toxicities to have occurred. Frozen glove contamination was analysed by 
determining frequencies and types of micro-organisms.   
 
Kaplan-Meier survival analyses were undertaken of data from participants who had 
undertaken 4 or more assessments to determine differences in time-to-event (an event 
being a score of 1 to 5 toxicity grading for erythroderma) between control and gloved 
hands. This analysis is a robust way of measuring, from a  pre-defined point, the time taken 
to experience a specified event[22]. The Wilcoxon matched-pairs analysis was used for non-
parametric data. Chi square and McNemar Chi Square tested categorical and binary 
variables. Differences between hands were investigated at the fourth assessment, as this is 
the time that the majority of patients participated in.  
 
Results  
 
Pilot study  
The pilot study tested the feasibility of implementing the intervention and the microbial 
testing protocol. Twenty-one participants were recruited into the pilot, however only fifteen 
of these proceeded with the frozen glove. The remaining six either withdrew before 
treatment commenced, or were unable to participate due to an altered treatment regimen 
or logistical issues. Those who commenced frozen glove treatment comprised thirteen 
women and two men, with a mean age of 54.8 years. Of note, the pilot study adhered to the 
manufacturer’s guidelines, that is, the gloves were frozen to minus 250C prior to use. Only 
seven pilot study patients completed 3 or more cycles for evaluation. The remaining six 
patients withdrew before Cycle 3, citing dissatisfaction with the glove temperature.  
 
Main study 
The second phase of the study accounted for the high attrition in the pilot study due to 
patients’ discomfort with the glove temperature and to align the intervention with usual 
clinical, rather than recommended research, practice. Standard clinical practice is to freeze 
the gloves in a domestic freezer with a temperature of approximately minus 40C. A recent 
study found that 100% of participants similarly complained of discomfort at least once when 
using gloves frozen to minus 250C or lower[23]; however less toxicity and less discomfort 
were observed when Ishiguro et al. increased the temperature by up to 15 degrees. Hence 
in the main study, ethical approval was obtained to amend the protocol to freezing of the 
gel glove for at least 12 hours at minus 40C to minus 100C prior to use. Figure 2 outlines 
participant flow in the study. 
 
Insert Figure 2 about here 
 
21 of the 53 participants enrolled in the main study completed evaluable data (i.e. 4 or more 
assessments); the reminaining 32 withdrew due to dissatisfaction with the glove 
temperature or immobility constraints. Their demographics and medical variables are 
presented in Table 2. The mean incidence and mean severity of toxicities are presented in 
Table 3.  
 
Insert Tables 2 and 3 about here 
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Kaplan Meier analysis demonstrated no significant difference between hand conditions in 
terms of time to event. At assessment 4, no participant demonstrated any significant 
difference in toxicity between gloved and non-gloved hands. Time to onset is presented in 
Table 4. 
 
Insert Table 4 about here 
 
 
All swabs taken throughout the project returned negative results for Staphylococcus aureus 
(MRSA), vancomycin-resistant Entercoccus (VRE) and carbapenem-resistant A. baumannii 
(CRAB). 
 
DISCUSSION 
This study investigated the safety and the efficacy of frozen glove therapy for hand and nail 
toxicities arising from docetaxel therapy. In terms of safety, the double and triple glove 
techniques trialled here are acceptable. There was no carriage of microbial organisms on 
the surface on any of the gel gloves at any time point. In terms of efficacy, however, 
cryotherapy did not appear to reduce the incidence, severity and time-to-onset of 
docetaxel-induced cutaneous toxicities in this sample. These results are mirrored by another 
recent study, which investigated predictors and efficacy of frozen glove therapy for taxane-
induced hand and nail toxicities in 55 intervention patients and 146 controls[24]. Can et al 
reported a comparable demographic to the present study, in that the majority were females 
with a mean age of 53 years and a diagnosis of breast cancer[24]. Can et al similarly 
reported no statistically significant difference for nail toxicity between intervention and 
control groups[24].  
 
While recognizing that the results of our study do not align with the findings of studies that 
report benefit from cryotherapy intervention for cutaneous toxicities[8, 11, 17, 18, 23], we 
have determined that this intervention is of limited value in our clinical context. The reasons 
are several. As indicated by the high withdrawal rate, individual patients did not tolerate the 
frozen glove particularly well. Moreover in the open plan design of our chemotherapy clinic, 
where patients are closely spaced and can see and interact with each other freely, an 
obvious intervention like the frozen glove draws a great deal of interest. Study participants 
tended to collectively discuss their negative experience of the glove with other potential 
participants. Hence while the withdrawal rate of 66% in the pilot study lessened somewhat 
to 60% in the main study after adjusting the temperature of the glove, the overall effect of 
patient interaction in this study, which would probably be replicated in the clinical context if 
the intervention were formally introduced, was that many patients chose not to be involved 
or withdrew after discussing the intervention with other patients.  
 
In addition, the majority of nail changes we detected were cosmetic and not likely to 
interfere with patients’ quality of life. Qualitative comments from the patients indicated 
that the discomfort caused by the glove, and the lack of clinical efficacy they observed 
themselves, did not offset any potential benefits from the intervention. Furthermore, the 
logistics of administering the cryotherapy in our high volume, resource-stretched, and very 
crowded chemotherapy unit does not lend itself easily to this intervention. Clinical staff 
reported that it was disruptive and that the freezer took up valuable space in the unit. They 
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also found it difficult to juggle the extra load entailed in the intervention within their usual 
task assignments. Expecting clinical nurses to assume the burden of ensuring the gloves 
were adequately cooled each day, determining whether the freezer was at the right 
temperature and documenting this, and remembering to check the glove temperature 
during the procedure and changing gloves in response, in the context of an already 
considerable workload, is not realistic.  
 
Finally, the severity of cutaneous side effects is believed to be dependent on the amount of 
exposure to docetaxel; with a higher incidence of toxicities observed in patients scheduled 
for three or more cycles[25]. Given the change in length of docetaxel-containing treatment 
implemented during this study, wherein 3 x 21 day cycles of combination 
cyclophosphamide, epirubicin, 5-fluorouracil and docetaxel (FEC-D) became the norm for 
breast cancer patients in our facility, frozen glove therapy is largely unnecessary. This 
observation is supported by Ishiguro et al, who recently evaluated the efficacy and comfort 
of frozen glove therapy in 16 breast cancer patients prescribed docetaxel[23]. Their 
investigation evaluated toxicities in patients who received a minimum of 5 months 
docetaxel treatment[23]. None of these patients developed hand or nail toxicities before 
this time[23]. Further data from Can et al’s study of 201 patients also support this decision, 
indicating the only variable associated with the severity of toxicity is an increased number of 
taxane cycles[24]. 
 
Limitations  
This study is limited by its small sample size: it is not adequately powered. While more 
patients might have been enrolled, the main study was stopped at n=53 due to the high rate 
of discomfort with the intervention as reflected in the withdrawal rate. The small sample 
limits the generalisability of the results. Another limitation is that it was not practical to 
adhere to the manufacturer’s recommendations regarding glove temperature, hence the 
temperature was revised upwards to make the glove more acceptable to patients. While 
one other recent study reported that a more clinically-acceptable temperature does not 
interfere with the efficacy of cryotherapy[23], it could nonetheless have influenced these 
results. A final limitation is that it is impossible to determine the effect of granulocyte 
colony stimulating factor (GCSF) in this study. A possible reason for the lack of response to 
the glove in this study compared to other studies is that during the pilot phase it became 
facility policy to administer GCSF to all breast cancer patients from the first cycle of any 
chemotherapy associated with dose-limiting neutropenia. An incidental benefit of this 
practice could be protection from cutaneous effects.  
 
CONCLUSION 
The results of this study indicate that cryotherapy in the form of frozen gloves for the 
cutaneous toxicities associated with docetaxel is safe in terms of infection control. However, 
its efficacy in terms of reducing the incidence, severity and time to onset of toxicities could 
not be established. In addition, its feasibility in terms of patient satisfaction and logistical 
obstacles for chemotherapy unit staff is questionable. These limitations preclude its routine 
use in our clinical setting. 
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